The results supplementthe findings that miRNAs are differentially expressed in BTZ-resistant myeloma cells.miR-19a could be a possible prognostic biomarker for responsiveness to BTZ in MM patients.In order to overcome resistance and improve the level of responsiveness to BTZ, miR-19atargets such as SOCS3 and STAT3 could be tracked. This evidence concerns the gene SOCS3 and plasma cell myeloma.